Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-03-26
1996-01-16
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31505
Patent
active
054847885
ABSTRACT:
A method for suppressing an immune response in a mammal by systemically treating the mammal with an effective amount of buspirone that is capable of inhibiting classic contact hypersensitivity reactions.
REFERENCES:
patent: 3717634 (1973-02-01), Wu et al.
patent: 3976776 (1976-08-01), Wu et al.
patent: 4182763 (1980-01-01), Casten et al.
patent: 4351939 (1982-09-01), Simms et al.
patent: 4417049 (1983-11-01), Sims
patent: 4438119 (1984-03-01), Allen et al.
patent: 4468391 (1984-08-01), Voith
patent: 4515947 (1985-05-01), Sandefur et al.
patent: 4620006 (1986-10-01), Sandefur et al.
patent: 4634703 (1987-01-01), Kurtz et al.
patent: 4636563 (1987-01-01), Abou-Gharbia
patent: 4640921 (1987-02-01), Othmer et al.
patent: 4687772 (1987-08-01), Alderdice
patent: 4696927 (1987-09-01), Gittos et al.
patent: 4709027 (1987-11-01), Abou-Gharbia et al.
patent: 4732984 (1988-03-01), Abou-Gharbia et al.
patent: 4748240 (1988-05-01), Stack et al.
patent: 4777173 (1988-10-01), Shrotryia et al.
patent: 4788189 (1988-11-01), Glazer
patent: 4810789 (1989-03-01), Behme et al.
patent: 4812567 (1989-03-01), Abou-Gharbia
patent: 4851533 (1989-07-01), Abou-Gharbia
patent: 4883875 (1989-11-01), Abou-Gharbia
patent: 4895848 (1990-01-01), Traber et al.
patent: 4900835 (1990-02-01), Abou-Gharbia
patent: 4927934 (1990-05-01), Abou-Gharbia et al.
patent: 4940585 (1990-07-01), Hapworth et al.
patent: 4943428 (1990-07-01), Lucot et al.
patent: 4963557 (1990-10-01), Badger et al.
patent: 5015646 (1991-05-01), Simms
patent: 5032578 (1991-07-01), Horovitz
patent: 5053508 (1991-10-01), Schiehser et al.
patent: 5096908 (1992-05-01), Gidda et al.
patent: 5098889 (1992-03-01), Costall et al.
patent: 5114947 (1992-05-01), Imondi
patent: 5134140 (1992-07-01), Stack
patent: 5162322 (1992-11-01), Taylor, Jr. et al.
patent: 5167616 (1992-12-01), Haak et al.
patent: 5169638 (1992-12-01), Dennis et al.
patent: 5183819 (1993-02-01), Abou-Gharbia et al.
patent: 5185329 (1993-02-01), Gawin et al.
patent: 5187277 (1993-02-01), Komissarov et al.
patent: 5244902 (1993-09-01), Sharpe et al.
patent: 5290783 (1994-03-01), Sharpe et al.
Allen, L. E., et al., Arneimittel-Forsch, vol. 24, p. 917 (1974).
Ameisen, J. C., et al., "A New Interpretation of the involvement of Serotonin in Delayed-Type Hypersensitivity," J. Immunology, vol. 142, No. 9, pp. 3171-3179 (1989).
Arndt, K. A., et al., "The Pharmacology of Topical Therapy," Dermatology in General Medicine, Ch. 211, 2532-40, T. B. Fitzpatrick, A. Z. Eisen, K. Wolff, I. M. 1988.
Caccia, S., et al., "Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat," Xenobiotica 13 (3):147-153 (1983).
Blozovski and Sivadjian, "The Action of Serotonin, Reserpine and Other Pharmacological Agents on Sudoral Secretion", Chemical Abstracts, vol. 54, 21504 (1960).
Dostal, G. and Gamelli, R. L., "The Differential Effect of Corticosteroids on Wound Disruption Strength in Mice," Arch. Surg., vol. 125, pp. 636-640 (1990).
Eison, A. S., Temple, D. L., "Buspirone: Review of its Pharmacology and Current Perspectives on its Mechanism of Action," Am. J. Med., vol. 80, pp. 1-51 (1986).
Freire-Garabal, M., et al., "Effects of Buspirone on the Immunosuppressive Response to Stress in Mice," Arch. Int. Pharmacodyn., 314, 160-168 (1991).
Fishel, R., et al., "Cyclosporin A Impairs Wound Healing In Rats," J. Surg. Research, vol. 34, pp. 572-575 (1983).
Galli and Hammel, "Unequivocal Delayed Hypersensitivity in Mast Cell-Deficient and Beige Mice", Science, vol. 226, 710-13 (1984).
Goa, K. L., and Ward, A., "Buspirone: A Preliminary Review of Its Pharmacological Properties and Therapeutic Efficacy as an Anxiolytic," Drugs, vol. 32, pp. 114-129 (1986).
Goldberg, L., and Finnerty, R., "Comparative Efficacy of Buspirone and Diazepam in the Treatment of Anxiety," Am. J. Psychiatry, vol. 136, No. 9, pp. 1184-1187 (1979).
Hellstrand, K., and Hermodsson, M. S., "Role of Serotonin in the Cell Regulation of Human Natural Killer Cell Cytotoxicity," J. Immunology, vol. 139, No. 3 pp. 869-875 (1987).
Jann, M. W., "Buspirone: An Update on a Unique Anziolytic Agent," Pharmacotherapy, vol. 8, No. 1, pp. 100-116 (1988).
Jun, D. D., et al., J. Invest. Dermatol., vol. 90, p. 311 (1988).
Kligman, A. M., "The Comparative Histopathology of Male-Pattern Baldness and Senescent Baldness," Clinics in Dermatology, vol. 6, No. 4, pp. 108-118 (1988).
Metys, J., et al., "Inhibition of Passive cutaneous Anaphalaxis By Several Histamine (H.sub.1) and Serotonin Antagonists in the Rat," Agents and Actions, vol. 23, pp. 331-333 (1988).
Milburn, C. M., and Peroutka, S. J., J. Neurochem., vol. 52, pp. 1787-1792 (1989).
New, J. S., et al., "Buspirone Analogues, 2, Structure-Activity Relationships of Aromatic Imide Derivatives," J. Med. Chem., vol. 29, pp. 1476-1482 (1986).
Schroeder and Christophers, "Transient Absence of C5a-Specific Neutrophil Function in Inflammatory Disorders of the Skin", The Journal of investigative Dermatology, vol. 85, 194-98 (1985).
Seppala, T., et al., "Effects of Alcohol on Buspirone and Lorazepam Actions," Clin. Pharmacol. Ther., pp. 201-207 (1982).
Singh, G., Corticosteroids in Corneal Endothelial Wound Healing, Annals of Opthalmology, vol. 17, No. 1 (1985).
Taylor, D. P., "Buspirone, a New Approach to the Treatment of Anxiety," Faseb. J., vol. 2, pp. 2445-2452 (1988).
Tucker, "Inflammation in Acne Vulgaris: Leukocyte Attraction and Cytotoxicity by Comedonal Material", The Journal of Investigative Dermatology, vol. 74, 21-25 (1980).
vanWauwe, P., and Goossens, J. G., "Arabinogalactan-and Dextran-induced Ear Inflammation in Mice: Differential Inhibition by H1-antihisamines, 5-HT-Serotonin Antagonists and Lipoxygenase Blockers," Agents and Actions, vol. 28, pp. 78-82 (1989).
Wershil et al, "Mast Cell-Dependent Amplification of an Immunologically Nonspecific Inflammatory Response", Journal of Immunology, vol. 140, 2356-60 (1988).
Wong, D. T. W., et al., "Human Eosinophils Express Transforming Growth Factor-Alpha," J. Exp. Chem., vol. 172, pp. 673-681 (1990).
Wong, D. T. W., et al., "Eosinophils From Patients with Blood Eosinophilia Express Transforming Growth Factor .beta.1," Blood, vol. 78, pp. 2702-2707 (1991).
Wu, et al., J. Med. Chem., vol. 15, p. 477 (1972).
Arndt Kenneth A.
Galli Stephen L.
Meltzer Peter C.
Razdan Raj K.
Sard Howard P.
Beth Israel Hospital Association
Cintins Marianne M.
Spivack Phyllis G.
Zalesky Cheryl K.
LandOfFree
Buspirone as a systemic immunosuppressant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Buspirone as a systemic immunosuppressant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Buspirone as a systemic immunosuppressant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-309525